The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
- Order Number
- Package Size
- 100 µl
The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).
A chromosome 20q deletion is associated with about 5 % of primary MDS. The majority of cases have an interstitial deletion between 20q11.2 and q13.3. As a single anomaly, the del(20q) has a favorable prognosis.
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating a deletion of PTPRT at 20q12.
Aberrant Cell (typical results): One green (1G) and two orange (2O) signals, indicating a deletion of MYBL2 at 20q13.
Aberrant Cell (typical results): One green (1G) and one orange (1O) signal, indicating deletions of both loci, PTPRT at 20q12 and MYBL2 at 20q13.
- Bench et al (2000) Oncogene 19:3902-3913
- Wang et al (2000) Genomics 67:28-39
- Saunders et al (2005) Cancer Genet Cytogen 156:154-157